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Background-—Heterogeneity in the underlying processes that contribute to heart failure with preserved ejection fraction (HFpEF) is
increasingly recognized. Diabetes mellitus is a frequent comorbidity in HFpEF, but its impact on left ventricular and arterial
structure and function in HFpEF is unknown.
Methods and Results-—Weassessed the impact of diabetesmellitus on left ventricular cellular and interstitial hypertrophy (assessedwith
cardiacmagnetic resonance imaging, including T1mapping pregadoliniumandpostgadoliniumadministration), arterial stiffness (assessed
with arterial tonometry), and pulsatile arterial hemodynamics (assessed with in-ofﬁce pressure-ﬂow analyses and 24-hour ambulatory
monitoring) among 53 subjects with HFpEF (32 diabetic and 21 nondiabetic subjects). Despite few differences in clinical characteristics,
diabetic subjects with HFpEF exhibited a markedly greater left ventricular mass index (78.1 [95% CI, 70.4–85.9] g versus 63.6 [95% CI,
55.8–71.3] g; P=0.0093) and indexed extracellular volume (23.6 [95% CI, 21.2–26.1] mL/m2 versus 16.2 [95% CI, 13.1–19.4] mL/m2;
P=0.0008). Pronounced aortic stiffeningwas also observed in thediabetic group (carotid-femoral pulsewave velocity, 11.86 [95%CI, 10.4–
13.1] m/s versus 8.8 [95% CI, 7.5–10.1] m/s; P=0.0027), with an adverse pulsatile hemodynamic proﬁle characterized by increased
oscillatory power (315 [95%CI, 258–373]mWversus 190 [95%CI, 144–236]mW;P=0.0007), aortic characteristic impedance (0.154 [95%
CI, 0.124–0.183]mmHg/mLper secondversus 0.096 [95%CI, 0.072–0.121]mm Hg/mLper second;P=0.0024), and forward (59.5 [95%
CI, 52.8–66.1] mm Hg versus 40.1 [95% CI, 31.6–48.6] mm Hg; P=0.0010) and backward (19.6 [95% CI, 16.2–22.9] mmHg versus 14.1
[95% CI, 10.9–17.3] mm Hg; P=0.0169) wave amplitude. Abnormal pulsatile hemodynamics were also evident in 24-hour ambulatory
monitoring, despite the absence of signiﬁcant differences in 24-hour systolic blood pressure between the groups.
Conclusions-—Diabetes mellitus is a key determinant of left ventricular remodeling, arterial stiffness, adverse pulsatile
hemodynamics, and ventricular-arterial interactions in HFpEF.
Clinical Trial Registration-—URL: https://www.clinicaltrials.gov. Unique identiﬁer: NCT01516346. ( J Am Heart Assoc. 2019;8:
e011457. DOI: 10.1161/JAHA.118.011457.)
Key Words: arterial stiffness • diabetes mellitus • hemodynamics • heart failure with preserved ejection fraction • left
ventricular hypertrophy • magnetic resonance imaging • myocardial ﬁbrosis
T he burden of heart failure (HF) has markedly increasedover the past several years. Approximately half of HF is
secondary to HF with preserved ejection fraction (HFpEF),
which is anticipated to represent an even larger proportion of
the total burden of HF as the population ages.1 Multiple
therapies that provide clinical beneﬁt in HF with reduced EF
are available. However, proven pharmacologic interventions
to improve outcomes in HFpEF are currently lacking.
Patients with HFpEF have a substantial burden of comor-
bidities that may contribute to its pathophysiological
characteristics and may impact its prognosis and response
to therapy.
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Heterogeneity in the underlying processes that contribute
to HFpEF is increasingly recognized. Diabetes mellitus is a key
risk factor for HF, and a frequent comorbidity in patients with
HFpEF, which is associated with poor outcomes in this patient
population.2 Increased aortic stiffness, arterial dysfunction,
and cardiac remodeling have been reported in diabetic
patients in the general population, in patients with chronic
kidney disease, and in patients with left ventricular (LV)
systolic dysfunction.3–10 However, no data are available about
the inﬂuence of diabetes mellitus on LV remodeling/ﬁbrosis,
arterial stiffness, pulsatile arterial hemodynamics, and ven-
tricular-vascular interactions in HFpEF. HFpEF is often
accompanied by diabetes mellitus, obesity, and various other
comorbidities that impact LV remodeling and arterial func-
tion,3,11,12 but is associated with structural cardiovascular
abnormalities in its own right.13 Furthermore, HFpEF differs
from HF with reduced EF in terms of ventricular remodeling
and ventricular-arterial coupling patterns.14–18 Detailed hemo-
dynamic and cardiac phenotyping can provide important
insights into the pathophysiological characteristics of LV
remodeling, ﬁbrosis, and abnormal ventricular-arterial inter-
actions, which contribute to the pathophysiological charac-
teristics of HFpEF.19,20
In this study, we aimed to assess the impact of diabetes
mellitus on LV hypertrophy, diffuse myocardial ﬁbrosis, large
artery stiffness, ventricular-vascular interactions, and in-ofﬁce
and 24-hour pulsatile arterial hemodynamics in HFpEF.
Methods
We analyzed data from a previous phase 2 trial that was
designed to assess the effect of isosorbide dinitrate,
isosorbide dinitrate plus hydralazine, or placebo on pul-
satile hemodynamics and LV remodeling in HFpEF.21 The
current study used only baseline (preintervention) pheno-
typic data.
The data, analytic methods, and study materials are not
publicly available for purposes of reproducing the results or
replicating the procedures. Such data may be made available
to other researchers for collaborative research, through the
establishment of appropriate data sharing agreements and
regulatory approvals.
Study Population
Inclusion criteria for the trial included symptomatic HFpEF
(LVEF >50%), in addition to at least one of the following: (1)
prior hospitalization for decompensated HF; (2) short-term
treatment for HF requiring intravenous diuretics or hemoﬁl-
tration; (3) echocardiographic evidence for elevated ﬁlling
pressures22; (4) long-term treatment with a loop diuretic for
control of symptoms; (5) or an elevated NT-proBNP
(N-terminal pro-B-type natriuretic peptide). Subjects needed
to be on stable medical therapy for the past month. Exclusion
criteria included any rhythm other than sinus with native
conduction; noncardiac conditions that signiﬁcantly limit
exercise (orthopedic or neuromuscular); known hypertrophic,
inﬁltrative, or inﬂammatory cardiomyopathy; pericardial dis-
ease; signiﬁcant pulmonary disease; primary pulmonary
arteriopathy; acute coronary syndrome or coronary revascu-
larization within the past 60 days; clinically signiﬁcant
perfusion defects on stress imaging without subsequent
revascularization; signiﬁcant valvular disease (eg, moderate or
greater mitral regurgitation or aortic stenosis); uncontrolled
hypertension (systolic blood pressure [SBP] >180 mm Hg or
diastolic blood pressure [DBP] >100 mm Hg); prior reduced
LVEF <50% (ie, recovered EF); hemoglobin <10 g/dL; current
therapy with organic nitrates or hydralazine; and elevations in
liver function test results. The presence of HFpEF was
adjudicated by 2 cardiologists with expertise in HFpEF (J.A.C.
and P.Z.), and subjects with an alternative explanation for
symptoms were also excluded. The protocol was approved by
the institutional review boards of the Philadelphia Veterans
Affairs Hospital and the Hospital of the University of
Pennsylvania. All subjects provided written informed consent.
Diabetes mellitus was deﬁned as the use of antidiabetic
medications, a fasting plasma glucose level ≥126 mg/dL,
and/or a hemoglobin A1c level >6.5%. Enrollment was not
performed in regards to diabetic status and, therefore, there
was no matching procedure to enroll diabetic versus nondi-
abetic subjects in the parent trial.
Clinical Perspective
What Is New?
• Compared with nondiabetic subjects with heart failure with
preserved ejection fraction, diabetic subjects with heart
failure with preserved ejection fraction exhibit more left
ventricular hypertrophy, myocardial extracellular volume
expansion, pronounced aortic stiffening, and an adverse
pulsatile hemodynamic proﬁle, characterized by increased
oscillatory power, aortic characteristic impedance, and
forward and backward (reﬂected) wave amplitude.
• Abnormal pulsatile hemodynamics in the diabetic subgroup
with heart failure with preserved ejection fraction are also
evident in 24-hour ambulatory monitoring, despite the
absence of signiﬁcant differences in 24-hour systolic blood
pressure between the groups.
What Are the Clinical Implications?
• Heterogeneity in the underlying processes that contribute to
heart failure with preserved ejection fraction is increasingly
recognized.
• Diabetes mellitus is responsible for important differences in
relevant underlying phenotypes in this patient population.
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Echocardiography and Arterial Tonometry
Echocardiography was performed using a Vivid e9 or Vivid I
machine (General Electric, Fairﬁeld, CT). Echocardiographic
parameters of diastolic function were quantiﬁed according to
American Society of Echocardiography guidelines by a trained
cardiologist (P.Z.)22; each metric was quantiﬁed in triplicate,
with average values presented. Volumetric ﬂow was quantiﬁed
using pulse-wave Doppler measurements from the LV outﬂow
tract in the 5-chamber view (Figure 1) and the LV outﬂow
tract cross-sectional area measured in the parasternal long-
axis view, providing a time-resolved aortic ﬂow waveform.
Applanation tonometry was performed at the carotid,
radial, and femoral arteries using a high-ﬁdelity tonometer
(Millar Instruments, Houston, TX), with a single-lead ECG
recording. The ECG complex of the ECG was used as a ﬁducial
point. Surface measurements were obtained from the sternal
notch to the site of interrogation at the carotid and femoral
arteries to compute carotid-femoral pulse wave velocity (CF-
PWV), a measure of large artery stiffness. Speciﬁcally, the
path length was computed as the distance from the sternal
notch to the femoral interrogation site minus the distance
from the sternal notch to the carotid interrogation site.
Radial tonometric waveforms were calibrated using the
brachial SBP and DBP, obtained using a validated oscillomet-
ric device (Omron HEM-705CP [Omron Corp, Kyoto, Japan] or
Accutorr Plus [Datascope Corp, Paramus, NJ]), assuming no
brachial-to-radial ampliﬁcation. Mean arterial pressure was
computed as the mean pressure from the radial pressure
waveform. Carotid tonometry, calibrated using mean arterial
pressure and DBP, was used to obtain a central pressure
waveform (Figure 1). Tonometric signals were processed
using Sphygmocor software (AtCor Medical, Australia).
Central Pulsatile Arterial Hemodynamics
The pressure-ﬂow pair was used to perform pulsatile hemo-
dynamic analyses (Figure 2). Pressure-ﬂow analyses were
performed by a technician and overread by a cardiologist with
expertise in pressure-ﬂow analyses (J.A.C.). Custom-designed
software programmed in Matlab (R2014b; MathWorks, Nat-
ick, MA) was used to assess aortic pressure-ﬂow relations, as
described previously in detail.19,23 In brief, after alignment of
signal-averaged central pressure and ﬂow waveforms, we
computed aortic input impedance as the ratio of central
pressure/ﬂow in the frequency domain. Aortic root charac-
teristic impedance was quantiﬁed as the average of
impedance modulus at higher frequencies (Figure 2). Wave
separation analysis was performed to obtain the amplitude of
the forward and backward pressure waves. Reﬂection mag-
nitude was deﬁned as the ratio of backward/forward
pressure.
Ambulatory Central BP Monitoring and Pulse
Wave Analysis
Ambulatory BP monitoring over 24 hours was performed
using the Mobilograph device (IEM, Stolberg, Germany),
Figure 1. Measurement and signal averaging of central pressure and ﬂow using arterial tonometry and Doppler echocardiography.
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which measures brachial and central (aortic) BP, as well as
time-resolved waveforms, allowing for ambulatory pulse wave
analysis (including wave separation into forward and back-
ward waves, as shown in Figure 3).24–26 We analyzed data
over 24 hours, as well as daytime and nighttime indexes
separately.
Cardiac Magnetic Resonance Imaging: LV
Structure and Function
Cardiac magnetic resonance imaging (CMR) was performed in
44 of the studied subjects. Participants underwent a CMR
examination to assess LV structure and function using a 1.5-T
whole body magnetic resonance imaging scanner (Avanto or
Espree; Siemens Healthcare, Malvern, PA) equipped with a
phased-array cardiac coil. LV volumes and EF were deter-
mined using balanced steady-state free-precession cine
imaging. Typical parameters were as follows: repetition
time=2.6 milliseconds; echo time=1.3 milliseconds; phases=30;
slice thickness=8 mm;bandwidth=898 Hz/pixel;ﬂip angle=70°;
ﬁeld of view=300 to 340 mm2; matrix size=1929192; and
parallel imaging factor=2. LV short-axis stack cine images were
manually traced at end diastole and end systole using CMR42
software (Circle CVI, Calgary, AB, Canada). All magnetic
resonance imaging measurements were performed by a trained
technician and overread by a cardiologist with expertise in CMR
(J.A.C.). LV mass (LVM) was computed as the difference between
epicardial and endocardial volumes, multiplied by myocardial
density. LVM was normalized for height in meters raised to the
power of 1.7.27
We used amodiﬁed look-locker inversion recovery sequence
to assess T1 times before and after the IV administration of
gadolinium contrast (gadopentetate dimeglumine, 0.15 mmol/
kg or equivalent) in a midventricular short-axis slice.28,29 Scan
parameters for modiﬁed look-locker inversion recovery were as
follows: ﬁeld of view=340 mm2; matrix size=1449192; slice
thickness=6 mm; repetition time=2.4 milliseconds; echo
time=1.18 milliseconds; ﬂip angle=30°; band-
width=1000 Hz/pixel; and parallel imaging factor=2. Myocar-
dial T1 measurements were performed before and at several
time points (5, 10, 15, and 20–40 minutes) after gadolinium
administration. Modiﬁed look-locker inversion recovery was
performed with a 5-3-3 schema with 2 inversions (5 TIs
(inversion times) after inversion 1, 3 T1 recovery heartbeats,
and 3 TIs after inversion 2). All available blood and myocardial
T1 measurements were used to compute k (the myocardium-
blood partition coefﬁcient) as the slope of the myocardial 1/T1
over the blood 1/T1 change, via linear regression.29 The
fraction of myocardial tissue comprised by the extracellular
space (extracellular volume [ECV] fraction) equals k9(1he-
matocrit). Extracellular LV volume was computed as LV wall
volume multiplied by ECV. Cellular LV volume was computed as
LV wall volume multiplied by (1ECV).30
Subjects enrolled in the trial who demonstrated impaired
renal function precluding the administration of gadolinium
(estimated glomerular ﬁltration rate <30 mL/min per
1.73 m2) or signiﬁcant claustrophobia did not undergo CMR
measurements.
Statistical Analyses
Patient characteristics were summarized using standard
descriptive statistics. We compared general characteristics
of study subjects using the t test of the Mann-Whitney U test,
Figure 2. Quantiﬁcation of the aortic input impedance spectrum, aortic characteristic impedance, and wave separation analysis. Pb indicates
backward pressure; Pf, forward pressure; Zin, input impedance.
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as appropriate. Proportions were compared with the v2 or the
Fisher exact test, as appropriate.
For comparisons of cardiac phenotypes, we performed
adjusted and unadjusted analyses using t tests and ANCOVA,
respectively. For all comparisons of continuous variables,
normality was assessed with the Anderson-Darling test and
log transformations were applied as needed to improve
normality. In all cases, means and 95% CIs are expressed in
the native (linear) scale. Statistical signiﬁcance was deﬁned as
a 2-tailed P<0.05. All probability values presented are 2 tailed.
Statistical analyses were performed using the Matlab statis-
tics and machine learning toolbox (Matlab 2016b; Mathworks,
Natwick, MA) and SPSS for Mac v22 (SPSS Inc, Chicago, IL).
Results
General characteristics of study subjects are shown in Table 1.
Our sample included 32 diabetic and 21 nondiabetic subjects
with HFpEF. Compared with nondiabetic subjects, diabetic
subjects exhibited greater ofﬁce SBP (143 versus 129 mm Hg;
P=0.0241) and a greater frequency of statin use (75% versus
47.62%; P=0.0420). There were no signiﬁcant differences
between the groups in age, sex, race/ethnicity, body mass
index, DBP, history of coronary disease, history of hypertension,
vasoactive medication use, renal function, hematocrit, NT-
proBNP levels, or echocardiographic parameters of diastolic
function. Mean hemoglobin A1c in the diabetic group was 7.9%
(interquartile range, 6.9%–9.28%), andmean fasting glucose was
154 mg/dL (interquartile range, 99–212 mg/dL). Insulin, met-
formin, sulfonylurea, andGulcan-like peptide-1 receptor agonists
use were present in 56.25%, 31.25%, 16.13%, and 3.23% of
diabetic subjects, respectively. No subjects were receiving a-
glucosidase inhibitors, thiazolidinediones, dipeptidyl peptidase-4
inhibitors, or sodium-glucose cotransporter-2 inhibitors.
LV Structure and Function
Table 2 shows a comparison of subjects who underwent
versus those who did not undergo a CMR. Table 3 shows a
comparison of key parameters of LV remodeling and cellular
and interstitial expansion between diabetic and nondiabetic
subjects. Diabetic subjects exhibited a markedly greater LVM
(191 versus 148 g; P=0.0095; Figure 4), which was also true
Figure 3. Assessment of ambulatory central blood pressure and pulsatile hemodynamics.
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Table 1. Baseline Characteristics of the Study Population
Characteristics
Nondiabetic
Subjects (n=21) Diabetic Subjects (n=32) P Value
Age, y 64 (59.3–69.5) 63 (59–69) 0.92
Male sex 13 (61.90) 27 (84.38) 0.06
Race/ethnicity
White 8 (38.10) 13 (40.62) 0.69
Black 13 (61.90) 18 (56.25)
Other 0 (0.00) 1 (3.12)
Body mass index, kg/m2 34.57.8 37.76.2 0.11
Systolic BP, mm Hg 12920 14322 0.0241
Diastolic BP, mm Hg 77.511.6 76.215.8 0.77
Medical history
Myocardial infarction 1 (4.76) 6 (18.75) 0.23
Dyslipidemia 15 (71.43) 29 (90.62) 0.13
Coronary artery disease 7 (33.33) 13 (40.62) 0.59
Hypertension 16 (76.19) 30 (93.75) 0.10
Current smoker 5 (23.81) 4 (12.50) 0.46
Diabetic neuropathy  14 (45.16) 
Diabetic retinopathy  12 (38.71) 
Medication use
b Blockers 10 (47.62) 21 (65.62) 0.19
Aspirin 13 (61.90) 25 (78.12) 0.20
Clopidogrel 3 (14.29) 2 (6.25) 0.379
ACE inhibitors 9 (42.86) 15 (46.88) 0.77
ARBs 2 (9.52) 9 (28.12) 0.17
Loop diuretics 8 (38.10) 19 (59.38) 0.13
MRAs 1 (4.76) 1 (3.12) 1.00
Statins 10 (47.62) 24 (75.00) 0.04
Calcium-channel blocker 5 (23.81) 14 (43.75) 0.14
Thiazide diuretics 7 (33.33) 11 (34.38) 0.94
Warfarin 0 (0.00) 1 (3.12) 1.00
Insulin  18 (56.25) 
Metformin  10 (31.25) 
Sulfonylureas  5 (16.13) 
Gulcan-like peptide-1 receptor agonists  1 (3.23) 
Laboratory tests
NT-proBNP, pg/mL 166 (65–317) 317 (134–960) 0.10
eGFR, mL/min per 1.73 m2 77 (60–99.8) 66 (50.3–97.8) 0.39
Hematocrit, % 40.13.5 38.25.1 0.16
Hemoglobin A1c, % 6 (5.68–6.43) 7.9 (6.9–9.28) 
Fasting glucose, mg/dL 96 (89–103) 154 (99–212) 
Echocardiographic diastolic function parameters
E wave velocity, cm/s 77.924 82.723.9 0.51
Continued
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when LVM was adjusted for either body height (P=0.0079) or
body surface area (BSA; 78.1 versus 63.6 g; P=0.0093). The
ECV fraction tended to be greater in diabetic subjects (30.4%
versus 27.1%), but this difference was not signiﬁcant
(P=0.1096). The extracellular LV wall volume was markedly
increased in the diabetic group (52.7 versus 35.4 mL;
Table 1. Continued
Characteristics
Nondiabetic
Subjects (n=21) Diabetic Subjects (n=32) P Value
A wave velocity, cm/s 78.721.1 74.224.8 0.54
Mitral deceleration time, ms 22356 22542 0.89
Mitral annular septal e0, cm/s 62.2 (53.7–75) 59 (44.2–81.1) 0.62
Mitral annular lateral e0, cm/s 97.8 (74–111.4) 84.3 (53.2–106.5) 0.11
E/e0 ratio 10.5 (8.4–12.8) 11.1 (9.4–14.2) 0.29
LV ejection fraction, % 61.86.6 61.58.1 0.88
Numbers represent the meanSD, median (interquartile range), or count (percentage). ACE indicates angiotensin-converting enzyme; ARB, angiotensin II receptor blocker; BP, blood
pressure; eGFR, estimated glomerular ﬁltration rate; LV, left ventricular; MRA, mineralocorticoid receptor antagonist; NT-proBNP, N-terminal pro-B-type natriuretic peptide; E, mitral peak
velocity of early ﬁlling; e0 , early dialostic mitral annular velocity.
Table 2. Comparison of General Characteristics Between Subjects Who Underwent Versus Those Who Did Not Undergo CMR
Characteristics
Subjects Who Underwent
CMR (n=44)
Subject Who Did Not
Undergo CMR (n=9) P Value
Age, y 62 (59–67) 68 (60.8–80.3) 0.17
Male sex 31 (70.45) 9 (100.00) 0.09
Race/ethnicity
White 17 (38.64) 4 (44.44) 0.87
Black 26 (59.09) 5 (55.56)
Other 1 (2.27) 0 (0.00)
Body mass index, kg/m2 36.66.8 35.68.2 0.70
Systolic BP, mm Hg 15020 15018 0.99
Diastolic BP, mm Hg 85.912 8417.4 0.72
Medical history
Myocardial infarction 6 (13.64) 0 (0.00) 0.57
Dyslipidemia 38 (86.36) 6 (66.67) 0.17
Coronary artery disease 17 (38.64) 3 (33.33) 1.00
Hypertension 40 (90.91) 6 (66.67) 0.09
Current smoker 8 (18.60) 1 (11.11) 1.00
Diabetic neuropathy 12 (27.27) 2 (25.00) 1.00
Diabetic retinopathy 11 (25.00) 1 (12.50) 0.66
Medication use
b Blockers 26 (59.09) 5 (55.56) 1.00
Aspirin 30 (68.18) 8 (88.89) 0.42
Clopidogrel 4 (9.09) 1 (11.11) 1.00
ACE inhibitors 21 (47.73) 3 (33.33) 0.49
ARBs 10 (22.73) 1 (11.11) 0.67
Loop diuretics 25 (56.82) 2 (22.22) 0.08
MRAs 2 (4.55) 0 (0.00) 1.00
Statins 29 (65.91) 5 (55.56) 0.71
Continued
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P=0.0003; Figure 4). The extracellular wall volume indexed for
BSA was markedly increased in the diabetic group (23.6
versus 16.2 mL/m2; P=0.0008). There were also between-
group differences in cellular wall volume (123 versus 97 mL;
P=0.0307), which, however, did not reach statistical signiﬁ-
cance when indexed for BSA (P=0.0526).
The lower panel of Table 3 shows comparisons adjusted for
statin use and SBP. In these adjusted comparisons, LVM was
signiﬁcantly greater in diabetic subjects (190 versus 149 g;
P=0.0299). Diabetic subjects also exhibited greater LVM
indexed for BSA or body height. The extracellular wall volume
was markedly greater in the diabetic subgroup (35.8 versus
52.3 mL; P=0.0036), whereas the cellular wall volume was not
signiﬁcantly different between the groups with or without
indexing for BSA (P=0.1796 and P=0.1176), respectively.
Differences in Arterial Stiffness and Aortic
Pulsatile Hemodynamics
Figure 5 and Table 4 show differences in large artery stiffness
and aortic pulsatile hemodynamics between the groups. Diabetic
subjects demonstrated amarked increase in large artery stiffness
(CF-PWV, 11.8 versus 8.8 m/s; P=0.0027). Although aortic
(central) SBP or DBP was not signiﬁcantly different between the
groups (Table 4), marked differences in pulsatile hemodynamics
were present. Aortic (central) pulse pressure was greater in the
diabetic group (59.2 versus 44.5 mm Hg; P=0.0118). There was
a marked increase in proximal aortic characteristic impedance
(0.154 versus 0.096 mm Hg/mL per second; P=0.0024). There
was a proportional increase in forward wave amplitude (59.5
versus 40.1 mm Hg) and backward wave amplitude (19.6 versus
14.1 mm Hg; Figure 5), without signiﬁcant differences in reﬂec-
tion magnitude (backward/forward pressure). Diabetic subjects
also exhibited a markedly greater oscillatory power (315 versus
190 mW; P=0.0007), without signiﬁcant differences in steady
power. In analyses adjusted for statin use, these trends did not
substantially change (Table 4, bottom part).
There were no signiﬁcant differences in stroke volume (88
[95% CI, 80.2–95.7] mL versus 80.4 [95% CI, 70.5–90.3] mL)
or cardiac output (5.49 [95% CI, 4.9–6.08] L/min versus 4.73
[95% CI, 4.07–5.39] L/min) between the groups. After
adjustment for mean arterial pressure and heart rate, CF-PWV
Table 2. Continued
Characteristics
Subjects Who Underwent
CMR (n=44)
Subject Who Did Not
Undergo CMR (n=9) P Value
Calcium-channel blocker 17 (38.64) 2 (22.22) 0.47
Thiazide diuretics 3 (33.33) 14 (31.82) 1.00
Warfarin 1 (2.27) 0 (0.00) 1.00
Insulin 15 (34.09) 3 (33.33) 1.00
Metformin 10 (22.73) 1 (12.50) 0.67
Sulfonylureas 4 (9.09) 1 (12.50) 0.58
Gulcan-like peptide-1 receptor agonists 1 (2.27) 0 (0.00) 1.00
Laboratory tests
NT-proBNP, pg/mL 228 (85–466) 415 (147–891) 0.38
eGFR, mL/min per 1.73 m2 66 (56–97.8) 80 (65.8–100.5) 0.41
Hematocrit, % 38.94.4 395.8 0.97
Hemoglobin A1c, % 7.2 (6.2–8.33) 6.5 (5.93–9.88) 0.96
Fasting glucose, mg/dL 103 (90–159) 104 (90–222) 0.91
Echocardiographic diastolic function parameters
E wave velocity, cm/s 80.824.1 82.123.8 0.91
A wave velocity, cm/s 75.123.3 82.325.7 0.52
Mitral deceleration time, ms 213 (190–251) 229 (226–257) 0.18
Mitral annular septal e0, cm/s 64.822.2 61.512.3 0.74
Mitral annular lateral e0, cm/s 94.3 (56.1–107.8) 82.3 (57–98.7) 0.63
E/e0 ratio 10.7 (8.8–12.9) 12.9 (9.7–14) 0.45
Numbers represent the meanSD, median (interquartile range), or count (percentage). ACE indicates angiotensin-converting enzyme; ARB, angiotensin II receptor blocker; BP, blood pressure;
CMR, cardiac magnetic resonance imaging; eGFR, estimated glomerular ﬁltration rate; MRA, mineralocorticoid receptor antagonist; NT-proBNP, N-terminal pro-B-type natriuretic peptide; E,
mitral peak velocity of early ﬁlling; e0 , early dialostic mitral annular velocity.
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was signiﬁcantly greater among diabetic subjects (11.6 [95%
CI, 10.2–13.0] m/s) compared with nondiabetic subjects
(8.9 [95% CI, 7.6–10.2] m/s; P=0.0069).
Ambulatory BP and Pulsatile Hemodynamics
There were no signiﬁcant differences in daytime, nighttime, or
24-hour brachial SBP, DBP, or aortic SBP (Table 5). In
contrast, highly signiﬁcant differences were observed in
brachial pulse pressure between the groups, with higher
daytime (58.5 versus 48.6 mm Hg; P=0.0078), nighttime
(55.1 versus 45.3 mm Hg; P=0.0006), and 24-hour (58.3
versus 47.5 mm Hg; P=0.0020) values in the diabetic group
(Table 5). Similarly, greater values of daytime (45.6 versus
36.8 mm Hg; P=0.0070), nighttime (43.5 versus 35.2 mm
Hg; P=0.0051), and 24-hour (46.5 versus 37.3 mm Hg;
P=0.0009) central pulse pressure were found in the
diabetic group. Diabetic subjects exhibited greater 24-hour
forward (29.5 versus 23.8 mm Hg; P=0.0011) and
backward (19.3 versus 15.3 mm Hg; P=0.0016) wave
amplitudes. Figure 6 demonstrates key differences in 24-
hour BP and arterial hemodynamic values between the
groups.
After adjustment for statin use and ofﬁce SBP, differences
persisted in nighttime and 24-hour central and aortic pulse
pressure, as well as in forward and backward wave amplitude
(Table 5).
Discussion
Using a combination of echocardiography, arterial tonometry,
and CMR, we compared LV remodeling, arterial structure and
function, and ofﬁce and ambulatory arterial pulsatile hemo-
dynamics between diabetic and nondiabetic subjects with
HFpEF. Despite similar age and few differences in standard
clinical characteristics, diabetic subjects with HFpEF exhibited
an increase in LVM, extracellular myocardial volume, and large
artery stiffness. Consistent with the hemodynamic effects of
large artery stiffening, diabetic subjects demonstrated
adverse pulsatile hemodynamics, with increased aortic char-
acteristic impedance, pulsatile power, forward and backward
wave amplitude, and aortic pulse pressure, demonstrated with
in-ofﬁce assessments, as well as 24-hour ambulatory moni-
toring. Interestingly, 24-hour central pulsatile hemodynamics
were substantially different between the groups, despite the
absence of signiﬁcant differences in 24-hour SBP. Our
Table 3. Comparison of Key Cardiovascular Parameters of LV Hypertrophy and Cellular and Interstitial Expansion Between
Diabetic and Nondiabetic Subjects
Parameters
Mean (95% CI)
P ValueNondiabetic Subjects Diabetic Subjects
Nonadjusted
LV mass, g 148 (124–172) 191 (171–211) 0.0095
LV mass indexed for BSA, g/m2 63.6 (55.8–71.3) 78.1 (70.4–85.9) 0.0093
LV mass indexed for height, g/m1.7 57 (49.5–64.5) 71.6 (63.9–79.3) 0.0079
Extracellular volume fraction, % 27.1 (24–30.2) 30.4 (28–32.8) 0.11
Cellular LV wall volume, mL 97 (80–114) 123 (106–139) 0.0307
Extracellular LV wall volume, mL 35.4 (29.4–41.4) 52.7 (45.8–59.6) 0.0003
Cellular LV wall volume index, mL/m2 43.5 (36.8–50.1) 52.3 (46.1–58.5) 0.053
Extracellular LV wall volume index, mL/m2 16.2 (13.1–19.4) 23.6 (21.2–26.1) 0.0008
Adjusted for systolic BP and statin use
LV mass, g 149 (124–174) 190 (169–211) 0.0220
LV mass indexed for BSA, g/m2 64.4 (56.2–72.7) 77.4 (69.5–85.4) 0.0299
LV mass indexed for height, g/m1.7 58.2 (50.1–66.2) 70.6 (62.8–78.4) 0.0336
Extracellular volume fraction, % 26.9 (23.4–30.4) 30.6 (27.9–33.2) 0.13
Cellular LV wall volume, mL 99 (80–119) 121 (103–139) 0.12
Extracellular LV wall volume, mL 35.8 (28.9–42.8) 52.3 (44.8–59.8) 0.0036
Cellular LV wall volume index, mL/m2 44.4 (36.6–52.1) 51.6 (45–58.3) 0.18
Extracellular LV wall volume index, mL/m2 16.4 (12.9–20) 23.5 (20.8–26.2) 0.0065
BP indicates blood pressure; BSA, body surface area; LV, left ventricular.
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ﬁndings underscore the importance of diabetes mellitus as a
determinant of LV structure, arterial stiffness, aortic pulsatile
hemodynamics, ventricular structure, and ventricular-arterial
interactions in HFpEF.
Aortic stiffness, measured as proximal aortic distensibility
with magnetic resonance imaging31 or CF-PWV,32 has been
shown to be increased in HFpEF, and to correlate with aerobic
capacity in this population.31 However, the determinants of
aortic stiffness in HFpEF are poorly understood. Moreover, the
heterogeneity in the underlying processes that contribute to
HFpEF is increasingly recognized, and may be responsible for
the failure of various candidate therapeutic interventions to
improve outcomes in this patient population. Therefore, there
is a great interest in a better phenotypic and mechanistic
characterization of readily identiﬁable patient subgroups with
HFpEF. Diabetes mellitus is a frequent comorbidity in HFpEF,
and is associated with poor outcomes in this patient
population, but its impact on arterial stiffness, pulsatile
hemodynamics, and ventricular-arterial interactions in HFpEF
is unknown. Our study demonstrates, for the ﬁrst time, that
diabetic patients with HFpEF exhibit a distinct phenotypic
proﬁle, with pronounced aortic stiffening compared with their
nondiabetic counterparts. The differences in CF-PWV between
diabetic and nondiabetic subjects (3 m/s) is striking and
equivalent to several decades of aging of the arterial tree. It is
also more pronounced than reported in the literature for
subjects without HFpEF. In the general population, diabetes
mellitus was associated with an 0.74-m/s increase in
middle-aged adults,5 and in general, diabetes mellitus tended
to have a relatively small effect on PWV, compared with BP
and age33; the effect of diabetes mellitus on CF-PWV was
estimated to be somewhat larger (1.67 m/s) among adults
with chronic kidney disease.9 In contrast, our study demon-
strated pronounced arterial stiffening (3-m/s greater CF-PWV
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Figure 4. Comparison of key cardiovascular parameters of left ventricular (LV) hypertrophy and cellular
and interstitial expansion between diabetic and nondiabetic subjects. DM indicates diabetes mellitus.
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values) in diabetic subjects with HFpEF, compared with their
nondiabetic HFpEF counterparts, despite the absence of
signiﬁcant differences in age or 24-hour SBP. Furthermore,
large differences in arterial stiffness persisted after adjust-
ment for ofﬁce SBP, which was slightly higher in the diabetic
group.
The mechanisms underlying arterial stiffening in diabetes
mellitus remain poorly understood. It has been proposed to
result from accelerated advanced glycation end product–
mediated collagen cross-linking,6,34 aortic wall calciﬁcation,35
endothelial dysfunction,36 chronic low-grade inﬂammation,
increased oxidative stress, and increased sympathetic tone.37
Advanced glycation end product formation results from several
reversible and irreversible steps that culminate in the detri-
mental cross-linking of collagen molecules within the arterial
vessel wall. In this process, sugar moieties (glucose, fructose,
and glycolytic adductions) interact with the free amino acid
residues of proteins, leading to the formation of Schiff base and
Amadori products. In the setting of hyperglycemia, Amadori
products are formed and unformed rapidly, and are in equilib-
rium with the blood glucose concentration.38 These reversible
Amadori products undergo slow rearrangements, ultimately
leading to the irreversible formation of advanced glycation end
products.39 Advanced glycation end product deposition on
arterial wall collagen leads to pathologic cross-linking through-
out the collagen molecule, which may contribute to an
increased collagen content and stiffness. A relationship
between inactive matrix Gla-protein (MGP; dephospho-uncar-
boxylated MGP), an inhibitor of vascular calciﬁcation, and CF-
PWV has also been recently demonstrated in diabetic sub-
jects.40 MGP is a small protein secreted by the vascular smooth
muscle cells, which undergoes vitamin K–dependent
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Figure 5. Differences in aortic pulsatile hemodynamics assessed via pressure-ﬂow analyses, between
diabetic and nondiabetic subjects. DM indicates diabetes mellitus; PP, pulse pressure; PWV, pulse wave
velocity; Zc, characteristic impedance.
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posttranslational activation. Active MGP is a potent inhibitor of
vascular calciﬁcation. In a mouse model of diabetes mellitus
with MGP gene deletion, elevated glucose levels lead to
increased BMP (bone morphogenetic protein) signaling,
endothelial-mesenchymal transitioning, and osteoinduction,41
which was limited by transgenic enhancement of MGP expres-
sion.
Increased aortic stiffness promotes adverse hemodynam-
ics via several key mechanisms. First, aortic stiffening
increases aortic root characteristic impedance, leading to a
steeper pressure-ﬂow relation in early systole, a wider pulse
pressure, and greater forward-wave amplitude. Second,
increased aortic PWV from aortic stiffening promotes a
premature arrival of reﬂected waves from the periphery to
the aorta, while the LV is still ejecting blood, leading to
excessive LV afterload and increased myocardial oxygen
consumption.19,20,42,43 A premature arrival of the reﬂected
wave also results in a reduction in diastolic pressure
augmentation by the reﬂected wave, resulting in a reduced
coronary perfusion gradient during diastole.42 Finally, an
increase in large artery stiffness leads to excessive penetra-
tion of pulsatility from large arteries into the microvascula-
ture of organs that require torrential blood ﬂow (such as the
kidney and the brain), which may contribute to end-organ
microvascular damage.44–46
The impact of diabetes mellitus on aortic root stiffness and
pulsatile hemodynamics has not been previously examined in
HFpEF. Aortic pulsatile hemodynamics are best assessed via
analyses of aortic pressure-ﬂow relations, which allow for a
comprehensive characterization of arterial load and ventric-
ular-arterial interactions.23,47 We found a pronounced
increase in proximal aortic characteristic impedance in the
Table 4. Differences in Aortic Pulsatile Hemodynamics Assessed Via Pressure-Flow Analyses, Between Diabetic and Nondiabetic
Subjects
Parameters
Mean (95% CI)
P ValueNondiabetic Subjects Diabetic Subjects
Nonadjusted
Carotid-femoral PWV, m/s 8.8 (7.5–10.1) 11.8 (10.4–13.1) 0.0027
Central SBP, mm Hg 121 (110–131) 133 (124–142) 0.0776
Central DBP, mm Hg 74.5 (67.4–81.6) 73.1 (67.5–78.6) 0.76
Central MAP, mm Hg 93.4 (85.8–101) 95.4 (89.4–101.4) 0.67
Central PP, mm Hg 44.5 (36.3–52.6) 59.2 (50.9–67.5) 0.0118
Aortic root Zc, mm Hg/mL per second 0.096 (0.072–0.121) 0.154 (0.124–0.183) 0.0024
Reflection magnitude 0.386 (0.345–0.427) 0.357 (0.325–0.389) 0.29
Forward wave amplitude, mm Hg 40.1 (31.6–48.6) 59.5 (52.8–66.1) 0.0010
Backward wave amplitude, mm Hg 14.1 (10.9–17.3) 19.6 (16.2–22.9) 0.0169
Oscillatory power, mW 190 (144–236) 315 (258–373) 0.0007
Steady power, mW 980 (819–1142) 1164 (1017–1311) 0.09
Adjusted for statin use
Carotid-femoral PWV, m/s 9.1 (7.7–10.5) 11.5 (10.2–12.9) 0.0165
Central SBP, mm Hg 122 (111–133) 132 (123–141) 0.16
Central DBP, mm Hg 74.1 (66.8–81.5) 73.3 (67.6–78.9) 0.86
Central MAP, mm Hg 93.6 (85.7–101.5) 95.3 (89.1–101.5) 0.74
Central PP, mm Hg 46 (37.5–54.6) 58 (49.9–66.1) 0.0452
Aortic root Zc, mm Hg/mL per second 0.102 (0.077–0.127) 0.149 (0.121–0.176) 0.0137
Reflection magnitude 0.381 (0.338–0.423) 0.36 (0.328–0.393) 0.47
Forward wave amplitude, mm Hg 41.4 (32.7–50.2) 58.7 (52–65.4) 0.0045
Backward wave amplitude, mm Hg 14.4 (11–17.7) 19.4 (16–22.8) 0.0359
Oscillatory power, mW 194 (145–242) 311 (253–370) 0.0024
Steady power, mW 966 (801–1132) 1174 (1022–1326) 0.07
DBP indicates diastolic blood pressure; MAP, mean arterial pressure; PP, pulse pressure; PWV, pulse wave velocity; SBP, systolic blood pressure; Zc, characteristic impedance; E (mitral
peak velocity of early ﬁlling); e' (early dialostic mitral annular velocity). Please remove GLP and use full expansion gulcan-like peptide-1 receptor agonists.
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diabetic group. The proximal aorta exerts an important
inﬂuence on central pulse pressure and is not assessed with
usual measurements of CF-PWV. Aortic root characteristic
impedance depends on its size and stiffness, and determines
the pulsatile pressure increase for any given ﬂow rate.23,47
Consistent with the observed increased aortic stiffness, PWV,
and characteristic impedance, we found a pronounced
increase in oscillatory power (which is the product of pulsatile
Table 5. Differences in Ambulatory BP and Pulsatile Hemodynamics Between Diabetic and Nondiabetic Subjects
Parameters
Mean (95% CI)
P ValueNondiabetic Subjects Diabetic Subjects
Unadjusted
Daytime brachial SBP 131 (121–141) 138 (131–146) 0.27
Daytime central SBP 120 (111–130) 128 (120–136) 0.23
Daytime DBP 82.7 (76.6–88.8) 79.7 (75.2–84.3) 0.45
Daytime brachial PP 48.6 (43–54.1) 58.5 (54.4–62.7) 0.0078
Daytime central PP 36.8 (32.4–41.3) 45.6 (41.3–50) 0.0070
Nighttime brachial SBP 117 (107–127) 129 (122–137) 0.07
Nighttime central SBP 108 (99–118) 117 (109–124) 0.18
Nighttime DBP 71.5 (64.2–78.8) 73.2 (67.7–78.8) 0.72
Nighttime brachial PP 45.3 (41.5–49.1) 55.1 (51.6–58.6) 0.0006
Nighttime central PP 35.2 (31–39.4) 43.5 (40.1–46.8) 0.0051
24-h Brachial SBP 126 (117–135) 135 (128–142) 0.13
24-h Central SBP 116 (107–124) 125 (119–132) 0.09
24-h DBP 79 (73.2–84.9) 77.9 (73.5–82.3) 0.76
24-h Brachial PP 47.5 (42.4–52.6) 58.3 (54.5–62.1) 0.0020
24-h Central PP 37.3 (33.3–41.3) 46.5 (43.5–49.5) 0.0009
24-h Forward wave amplitude 23.8 (21.3–26.3) 29.5 (27.6–31.3) 0.0011
24-h Backward wave amplitude 15.3 (13.5–17.2) 19.3 (17.9–20.7) 0.0016
Adjusted for SBP (office) and statin use
Daytime brachial SBP 137 (129–145) 135 (129–141) 0.72
Daytime central SBP 126 (117–135) 125 (117–132) 0.82
Daytime DBP 85.7 (79.8–91.5) 78.1 (73.8–82.3) 0.0554
Daytime brachial PP 51.4 (46.4–56.3) 57 (53.3–60.6) 0.10
Daytime central PP 38.8 (34–43.6) 44.1 (40–48.3) 0.12
Nighttime brachial SBP 123 (114–132) 126 (119–132) 0.64
Nighttime central SBP 112 (103–122) 114 (107–121) 0.78
Nighttime DBP 75.5 (68.7–82.3) 70.9 (65.9–76) 0.32
Nighttime brachial PP 46.8 (42.9–50.8) 54.1 (50.7–57.4) 0.0113
Nighttime central PP 36.3 (31.9–40.7) 42.8 (39.3–46.3) 0.0359
24-h Brachial SBP 132 (123–140) 131 (125–137) 0.97
24-h Central SBP 120 (112–128) 123 (117–128) 0.69
24-h DBP 82.3 (76.7–87.8) 76.1 (72.1–80.1) 0.10
24-h Brachial PP 50.1 (45.4–54.8) 56.8 (53.4–60.2) 0.0363
24-h Central PP 38.5 (34.4–42.6) 45.8 (42.8–48.8) 0.0114
24-h Forward wave amplitude 24.8 (22.3–27.3) 28.9 (27.1–30.7) 0.0184
24-h Backward wave amplitude 15.7 (13.8–17.7) 19.1 (17.7–20.5) 0.0133
All units are in mm Hg. BP indicates blood pressure; DBP, diastolic BP; PP, pulse pressure; SBP, systolic BP.
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pressure and ﬂow) and increased forward wave amplitude,
backward wave amplitude, and central pulse pressure in the
diabetic group. This physiologic pattern was also evident from
24-hour ambulatory recordings.
Interestingly, despite the markedly abnormal pulsatile
hemodynamics found in 24-hour monitoring, 24-hour SBP
was not signiﬁcantly different between the groups. SBP is a
composite hemodynamic marker, which depends on both
mean pressure and pulse pressure. It follows that marked
SBP elevations may be absent despite adverse pulsatile
hemodynamics when mean pressure is low, which tends to
occur at the expense of a lower diastolic pressure. This
hemodynamic proﬁle, consistent with elevated arterial
stiffness, has been clearly associated with adverse outcomes
in non-HFpEF populations.48,49 Similarly, in the TOPCAT
(Treatment of Preserved Cardiac Function Heart Failure With
an Aldosterone Antagonist Trial), no relationship was
observed between baseline SBP quartiles and outcomes,50
whereas a low DBP predicted an increased risk of a
composite of all-cause death, nonfatal myocardial infarction,
nonfatal stroke, or hospitalization for HF in this cohort.51
Similarly, a high pulse pressure has been associated with all-
cause death in HFpEF.52
We also found that diabetic subjects exhibited signiﬁcantly
greater ofﬁce SBP, despite the absence of signiﬁcant
differences in 24-hour SBP. This may be because of a type
II error for ambulatory SBP, although it is possible that
diabetic subjects with HFpEF exhibit a greater white coat
effect. Future studies should address potential differences in
ofﬁce versus ambulatory BP measurements in diabetic versus
nondiabetic subjects with HFpEF and their prognostic impli-
cations.
No DM DM
Group
0
20
40
60
80
100
120
140
160
180
24
-h
ou
r b
ra
ch
ia
l S
B
P
No DM DM
Group
0
20
40
60
80
100
120
140
160
24
-h
ou
r c
en
tr
al
 S
B
P
No DM DM
Group
0
20
40
60
80
100
24
-h
ou
r D
B
P 
No DM DM
Group
0
10
20
30
40
50
60
24
-h
ou
r c
en
tr
al
 P
P 
P=0.0009
No DM DM
Group
0
5
10
15
20
25
30
35
40
24
-h
ou
r f
or
w
ar
d 
w
av
e 
am
pl
itu
de
 P=0.0011
No DM DM
Group
0
5
10
15
20
25
30
24
-h
ou
r b
ac
kw
ar
d 
w
av
e 
am
pl
itu
de
 
P=0.0016
Figure 6. Differences in ambulatory blood pressure (BP) and pulsatile hemodynamics between diabetic
and nondiabetic subjects. All units are in mm Hg. DBP indicates diastolic BP; DM, diabetes mellitus; PP,
pulse pressure; SBP, systolic BP.
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The effects of diabetes mellitus on arterial stiffness are
unlikely to be a consequence of the effects of diabetes
mellitus on the myocardium. First, our analyses included
quantiﬁcation of pressure-ﬂow relations, which intrinsically
account for the amount of ﬂow generated by the LV. Second,
the LVEF and stroke volume were not signiﬁcantly different
between the groups and are unlikely to explain the differences
in arterial stiffness and pulsatile load. Rather, our results are
consistent with the notion that diabetes mellitus exerts
adverse effects on the arterial tree. Interestingly, the
relationship between diabetes mellitus and arterial stiffness
may be bidirectional, as recent data suggest that arterial
stiffening may precede diabetes mellitus and predict the
incidence of diabetes mellitus in nondiabetic adults.53 Arterial
abnormalities associated with diabetes mellitus can adversely
impact the myocardium, given that increased and/or abnor-
mal pulsatile load favors LV hypertrophy, ﬁbrosis, and
diastolic dysfunction.3,15,17,18,43,54–57 Diabetes mellitus also
has primary effects on the myocardium, and likely provides a
“double hit” (ie, hemodynamic and metabolic) that may be
important for the development of HFpEF. The interactions
between the hemodynamic and the metabolic/neurohormonal
effects of diabetes mellitus in the pathogenesis of HFpEF
should be the focus of future studies.
Our study should be interpreted in the context of its
strengths and limitations. Our study is the ﬁrst to assess the
impact of type 2 diabetes mellitus arterial stiffness on
pulsatile hemodynamics and LV remodeling in HFpEF. We
assessed CF-PWV, the gold standard index of large artery
stiffness, in addition to comprehensive in-laboratory assess-
ments of proximal aortic pressure-ﬂow relations using state-
of-the-art techniques. We used measured ﬂow, as opposed to
synthetic or triangular ﬂow waveforms. We used carotid high-
ﬁdelity tonometry, which does not rely in the application of
transfer functions to peripheral pressure waveforms. In
addition, we assessed 24-hour ambulatory brachial and aortic
BP and pulsatile hemodynamics. We enrolled a multiethnic
cohort, which may be more generalizable to multiethnic
populations. Our assessments of LV remodeling included
measurements of LVM, as well as measures of cellular and
interstitial expansion using contemporary magnetic resonance
imaging techniques. Our study also has several limitations.
We applied strict inclusion/exclusion criteria during the
parent trial, to increase our conﬁdence in the inclusion of
subjects with HFpEF, as opposed to alternative causes of
symptoms. In the process, we may have excluded many
subjects with HFpEF and comorbidities related to arterial
stiffness, such as advanced renal disease and dementia. This
may have biased our study toward the null and may have
underestimated the effect of diabetes mellitus on arterial
stiffness. Our sample size is relatively small, although the
marked differences in the measured parameters resulted in
highly signiﬁcant between-group differences. We did not
perform signiﬁcance adjustments for multiple comparisons,
which may increase the a error rate. However, our results on
aortic stiffness (CF-PWV), in-ofﬁce pulsatile hemodynamics,
and 24-hour assessments are highly consistent, adding
conﬁdence to our results. We did not assess urinary albumin
excretion, an established renal and cardiovascular risk marker.
All phenotypes were measured in a blinded manner to the
randomized arm in the parent trial; strict blinding for diabetic
status was not done, as these comparisons were performed
retrospectively. Nevertheless, images were analyzed indepen-
dently of clinical data, and many of the examined phenotypes
(such as ECV computations, arterial stiffness measurements,
pressure-ﬂow analyses, and ambulatory BP monitoring–based
measurements) are not signiﬁcantly susceptible to systematic
operator bias. An additional limitation is that the potential
effect of intraobserver/interobserver variability was not
assessed, which may have limited our power to detect some
associations. Given the limited sample size, we did not perform
comprehensive adjustments for clinical characteristics, and
adjusted only for characteristics that differed between the
groups. Finally, our sample size was not sufﬁciently large to
explore the relationship between glycemic control and arterial
stiffness or LV remodeling/ﬁbrosis among diabetic subjects
with HFpEF. This should be the focus of future studies, given
that glycemic control has been shown to be an important
determinant of LV myocardial interstitial expansion in diabetic
subjects without HFpEF.58
In summary, we comprehensively characterized, for the
ﬁrst time, arterial stiffness and in-ofﬁce and pulsatile arterial
hemodynamic abnormalities in subjects with HFpEF with and
without diabetes mellitus. We demonstrate that diabetes
mellitus is associated with marked aortic stiffening, and an
adverse pulsatile hemodynamic proﬁle, characterized by
increased aortic characteristic impedance, pulsatile power,
forward and backward wave amplitude, and aortic pulse
pressure, despite the absence of signiﬁcant differences in 24-
hour SBP. Diabetic subjects also demonstrated more pro-
nounced LV hypertrophy, with expansion of the extracellular
myocardial compartment. Our ﬁndings underscore the impor-
tance of diabetes mellitus as a determinant of LV structure,
arterial stiffness, aortic pulsatile hemodynamics, and ventric-
ular-arterial interactions in HFpEF and indicate the need to
develop therapeutic approaches to mitigate arterial stiffening
and its consequences in diabetic subjects. These approaches
may be useful for the prevention and treatment of HFpEF.
Sources of Funding
This study was funded by a grant from the National Institute of
Aging (5R21AG043802-02, Chirinos) and grants from the
Veterans Affairs Health Network (VISN-4 CPPF program,
DOI: 10.1161/JAHA.118.011457 Journal of the American Heart Association 15
Diabetes Mellitus in HFpEF Chirinos et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
D
ow
nloaded from
 http://ahajournals.org by on August 9, 2019
Chirinos), 1R56HL124073-01A1 (Chirinos) and 1 R01
HL121510-01A1 (Chirinos). The project was also supported
by grant UL1RR024134 from the National Center for
Research Resources and by grant UL1TR000003 from the
National Center for Advancing Translational Sciences,
National Institutes of Health (NIH); the content is solely the
responsibility of the authors and does not necessarily
represent the ofﬁcial views of the NIH. Zamani was funded
by the Institute for Translational Medicine and Therapeutics of
the University of Pennsylvania (grant 5UL1TR000003-09 from
the National Center for Research Resources), 5-T32-
HL007843-17, 1-K23-HL-130, and 551-01.
Disclosures
Chirinos has received consulting honoraria from Bristol-Myers
Squibb, OPKO Healthcare, Fukuda-Denshi, Microsoft, Iron-
wood Pharmaceuticals, Saniﬁt, Pﬁzer, Akros Pharma, Merck,
and Bayer. He received research grants from the National
Institutes of Health, the American College of Radiology
Network, Fukuda Denshi, Bristol-Myers Squibb, and Microsoft;
and he received device loans from AtCor Medical, Unex, and
Uscom. Chirinos is named as inventor in a University of
Pennsylvania patent application for the use of inorganic
nitrates/nitrites for the treatment of heart failure and
preserved ejection fraction (HFpEF) and in a University of
Pennsylvania invention disclosure for the use of biomarkers in
HFpEF. The remaining authors have no disclosures to report.
References
1. Lam CS, Donal E, Kraigher-Krainer E, Vasan RS. Epidemiology and clinical
course of heart failure with preserved ejection fraction. Eur J Heart Fail.
2011;13:18–28.
2. Sandesara PB, O’Neal WT, Kelli HM, Samman-Tahhan A, Hammadah M,
Quyyumi AA, Sperling LS. The prognostic signiﬁcance of diabetes and
microvascular complications in patients with heart failure with preserved
ejection fraction. Diabetes Care. 2018;41:150–155.
3. Townsend RR, Wilkinson IB, Schiffrin EL, Avolio AP, Chirinos JA, Cockcroft JR,
Heffernan KS, Lakatta EG, McEniery CM, Mitchell GF, Najjar SS, Nichols WW,
Urbina EM, Weber T; American Heart Association Council on Hypertension.
Recommendations for improving and standardizing vascular research on
arterial stiffness: a scientiﬁc statement from the American Heart Association.
Hypertension. 2015;66:698–722.
4. Loehr LR, Meyer ML, Poon AK, Selvin E, Palta P, Tanaka H, Pankow JS, Wright
JD, Griswold ME, Wagenknecht LE, Heiss G. Prediabetes and diabetes are
associated with arterial stiffness in older adults: the ARIC study. Am J
Hypertens. 2016;29:1038–1045.
5. Chirinos JA, Segers P, Gillebert TC, De Buyzere ML, Van Daele CM, Khan ZA,
Khawar U, De Bacquer D, Rietzschel ER, Asklepios I. Central pulse pressure
and its hemodynamic determinants in middle-aged adults with impaired fasting
glucose and diabetes: the Asklepios study. Diabetes Care. 2013;36:2359–
2365.
6. Prenner SB, Chirinos JA. Arterial stiffness in diabetes mellitus. Atherosclerosis.
2015;238:370–379.
7. Shah AM, Hung CL, Shin SH, Skali H, Verma A, Ghali JK, Kober L, Velazquez EJ,
Rouleau JL, McMurray JJ, Pfeffer MA, Solomon SD. Cardiac structure and
function, remodeling, and clinical outcomes among patients with diabetes
after myocardial infarction complicated by left ventricular systolic dysfunction,
heart failure, or both. Am Heart J. 2011;162:685–691.
8. Townsend RR, Chirinos JA, Parsa A, Weir MA, Sozio SM, Lash JP, Chen J,
Steigerwalt SP, Go AS, Hsu CY, Rafey M, Wright JT Jr, Duckworth MJ,
Gadegbeku CA, Joffe MP; Chronic Renal Insufﬁciency Cohort Investigators.
Central pulse pressure in chronic kidney disease: a chronic renal insufﬁciency
cohort ancillary study. Hypertension. 2010;56:518–524.
9. Townsend RR, Wimmer NJ, Chirinos JA, Parsa A, Weir M, Perumal K, Lash JP,
Chen J, Steigerwalt SP, Flack J, Go AS, Rafey M, Rahman M, Sheridan A,
Gadegbeku CA, Robinson NA, Joffe M. Aortic PWV in chronic kidney disease: a
CRIC ancillary study. Am J Hypertens. 2010;23:282–289.
10. Lehrke M, Marx N. Diabetes mellitus and heart failure. Am J Med. 2017;130:
S40–S50.
11. Chirinos JA, Rietzschel ER, De Buyzere ML, De Bacquer D, Gillebert TC, Gupta
AK, Segers P; Asklepios investigators. Arterial load and ventricular-arterial
coupling: physiologic relations with body size and effect of obesity.
Hypertension. 2009;54:558–566.
12. Townsend RR, Black HR, Chirinos JA, Feig PU, Ferdinand KC, Germain M,
Rosendorff C, Steigerwalt SP, Stepanek JA. Clinical use of pulse wave analysis:
proceedings from a symposium sponsored by North American Artery. J Clin
Hypertens (Greenwich). 2015;17:503–513.
13. Mohammed SF, Borlaug BA, Roger VL, Mirzoyev SA, Rodeheffer RJ, Chirinos JA,
Redﬁeld MM. Comorbidity and ventricular and vascular structure and function
in heart failure with preserved ejection fraction: a community-based study.
Circ Heart Fail. 2012;5:710–719.
14. Chirinos JA, Sweitzer N. Ventricular-arterial coupling in chronic heart failure.
Card Fail Rev. 2017;3:12–18.
15. Weber T, Chirinos JA. Pulsatile arterial haemodynamics in heart failure. Eur
Heart J. 2018;39:3847–3854.
16. Chirinos JA, Akers SR, Trieu L, Ischiropoulos H, Doulias PT, Tariq A, Vassim I,
Koppula MR, Syed AA, Soto-Calderon H, Townsend RR, Cappola TP, Margulies
KB, Zamani P. Heart failure, left ventricular remodeling, and circulating nitric
oxide metabolites. J Am Heart Assoc. 2016;5:e004133. DOI: 10.1161/JAHA.
116.004133.
17. Chirinos JA. Ventricular-arterial coupling: invasive and non-invasive assess-
ment. Artery Res. 2013;7:2–14.
18. Ky B, French B, May Khan A, Plappert T, Wang A, Chirinos JA, Fang JC, Sweitzer
NK, Borlaug BA, Kass DA, St John Sutton M, Cappola TP. Ventricular-arterial
coupling, remodeling, and prognosis in chronic heart failure. J Am Coll Cardiol.
2013;62:1165–1172.
19. Chirinos JA. Deep phenotyping of systemic arterial hemodynamics in HFpEF
(part 1): physiologic and technical considerations. J Cardiovasc Transl Res.
2017;10:260.
20. Chirinos JA. Deep phenotyping of systemic arterial hemodynamics in HFpEF
(part 2): clinical and therapeutic considerations. J Cardiovasc Transl Res.
2017;10:261–274.
21. Zamani P, Akers S, Soto-Calderon H, Beraun M, Koppula MR, Varakantam S,
Rawat D, Shiva-Kumar P, Haines PG, Chittams J, Townsend RR, Witschey
WR, Segers P, Chirinos JA. Isosorbide dinitrate, with or without
hydralazine, does not reduce wave reﬂections, left ventricular hypertrophy,
or myocardial ﬁbrosis in patients with heart failure with preserved ejection
fraction. J Am Heart Assoc. 2017;6:e004262. DOI: 10.1161/JAHA.116.
004262.
22. Nagueh SF, Appleton CP, Gillebert TC, Marino PN, Oh JK, Smiseth OA,
Waggoner AD, Flachskampf FA, Pellikka PA, Evangelista A. Recommendations
for the evaluation of left ventricular diastolic function by echocardiography. J
Am Soc Echocardiogr. 2009;22:107–133.
23. Chirinos JA, Segers P. Noninvasive evaluation of left ventricular afterload: part
2: arterial pressure-ﬂow and pressure-volume relations in humans. Hyperten-
sion. 2010;56:563–570.
24. Hametner B, Wassertheurer S, Kropf J, Mayer C, Holzinger A, Eber B, Weber T.
Wave reﬂection quantiﬁcation based on pressure waveforms alone—methods,
comparison, and clinical covariates. Comput Methods Programs Biomed.
2013;109:250–259.
25. Wassertheurer S, Kropf J, Weber T, van der Giet M, Baulmann J, Ammer M,
Hametner B, Mayer CC, Eber B, Magometschnigg D. A new oscillometric
method for pulse wave analysis: comparison with a common tonometric
method. J Hum Hypertens. 2010;24:498–504.
26. Weber T, Wassertheurer S, Rammer M, Maurer E, Hametner B, Mayer CC,
Kropf J, Eber B. Validation of a brachial cuff-based method for estimating
central systolic blood pressure. Hypertension. 2011;58:825–832.
27. Chirinos JA, Segers P, De Buyzere ML, Kronmal RA, Raja MW, De Bacquer D,
Claessens T, Gillebert TC, St John-Sutton M, Rietzschel ER. Left ventricular
mass: allometric scaling, normative values, effect of obesity, and prognostic
performance. Hypertension. 2010;56:91–98.
28. Messroghli DR, Greiser A, Frohlich M, Dietz R, Schulz-Menger J. Optimization
and validation of a fully-integrated pulse sequence for modiﬁed look-locker
inversion-recovery (MOLLI) T1 mapping of the heart. J Magn Reson Imaging.
2007;26:1081–1086.
DOI: 10.1161/JAHA.118.011457 Journal of the American Heart Association 16
Diabetes Mellitus in HFpEF Chirinos et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
D
ow
nloaded from
 http://ahajournals.org by on August 9, 2019
29. Liu CY, Liu YC, Wu C, Armstrong A, Volpe GJ, van der Geest RJ, Liu Y, Hundley
WG, Gomes AS, Liu S, Nacif M, Bluemke DA, Lima JA. Evaluation of age-related
interstitial myocardial ﬁbrosis with cardiac magnetic resonance contrast-
enhanced T1 mapping: MESA (Multi-Ethnic Study of Atherosclerosis). J Am Coll
Cardiol. 2013;62:1280–1287.
30. McDiarmid AK, Swoboda PP, Erhayiem B, Lancaster RE, Lyall GK, Broadbent
DA, Dobson LE, Musa TA, Ripley DP, Garg P, Greenwood JP, Ferguson C, Plein
S. Athletic cardiac adaptation in males is a consequence of elevated myocyte
mass. Circ Cardiovasc Imaging. 2016;9:e003579.
31. Hundley WG, Kitzman DW, Morgan TM, Hamilton CA, Darty SN, Stewart KP,
Herrington DM, Link KM, Little WC. Cardiac cycle-dependent changes in aortic
area and distensibility are reduced in older patients with isolated diastolic
heart failure and correlate with exercise intolerance. J Am Coll Cardiol.
2001;38:796–802.
32. Weber T, Wassertheurer S, O’Rourke MF, Haiden A, Zweiker R, Rammer M,
Hametner B, Eber B. Pulsatile hemodynamics in patients with exertional
dyspnea: potentially of value in the diagnostic evaluation of suspected heart
failure with preserved ejection fraction. J Am Coll Cardiol. 2013;61:1874–1883.
33. Cecelja M, Chowienczyk P. Dissociation of aortic pulse wave velocity with risk
factors for cardiovascular disease other than hypertension: a systematic
review. Hypertension. 2009;54:1328–1336.
34. Monnier VM, Vishwanath V, Frank KE, Elmets CA, Dauchot P, Kohn RR.
Relation between complications of type I diabetes mellitus and collagen-linked
ﬂuorescence. N Engl J Med. 1986;314:403–408.
35. Towler DA. Arteriosclerotic calciﬁcation: a serpi(n)ginous path to cardiovas-
cular health? Circ Res. 2015;117:744–746.
36. Brillante DG, O’Sullivan AJ, Johnstone MT, Howes LG. Arterial stiffness and
haemodynamic response to vasoactive medication in subjects with insulin-
resistance syndrome. Clin Sci (Lond). 2008;114:139–147.
37. Weber T. Arterial stiffness, wave reﬂections, and diabetes: a bidirectional
relationship? Am J Hypertens. 2010;23:1047–1048.
38. Brownlee M, Vlassara H, Kooney A, Ulrich P, Cerami A. Aminoguanidine
prevents diabetes-induced arterial wall protein cross-linking. Science.
1986;232:1629–1632.
39. Sell DR, Monnier VM. Molecular basis of arterial stiffening: role of glycation—a
mini-review. Gerontology. 2012;58:227–237.
40. Sardana M, Vasim I, Varakantam S, Kewan U, Tariq A, Koppula MR, Syed AA,
Beraun M, Drummen NE, Vermeer C, Akers SR, Chirinos JA. Inactive matrix
Gla-protein and arterial stiffness in type 2 diabetes mellitus. Am J Hypertens.
2017;30:196–201.
41. Yao Y, Jumabay M, Ly A, Radparvar M, Cubberly MR, Bostrom KI. A role for the
endothelium in vascular calciﬁcation. Circ Res. 2013;113:495–504.
42. Hoffman JI, Buckberg GD. The myocardial oxygen supply: demand index
revisited. J Am Heart Assoc. 2014;3:e000285. DOI: 10.1161/JAHA.113.
000285.
43. Chirinos JA. Deciphering systolic-diastolic coupling in the intact heart.
Hypertension. 2017;69:575–577.
44. Cardoso CR, Ferreira MT, Leite NC, Barros PN, Conte PH, Salles GF.
Microvascular degenerative complications are associated with increased aortic
stiffness in type 2 diabetic patients. Atherosclerosis. 2009;205:472–476.
45. Kim WJ, Park CY, Park SE, Rhee EJ, Lee WY, Oh KW, Park SW, Kim SW, Song S.
The association between regional arterial stiffness and diabetic retinopathy in
type 2 diabetes. Atherosclerosis. 2012;225:237–241.
46. Smith A, Karalliedde J, De Angelis L, Goldsmith D, Viberti G. Aortic pulse wave
velocity and albuminuria in patients with type 2 diabetes. J Am Soc Nephrol.
2005;16:1069–1075.
47. Chirinos JA, Segers P. Noninvasive evaluation of left ventricular afterload: part
1: pressure and ﬂow measurements and basic principles of wave conduction
and reﬂection. Hypertension. 2010;56:555–562.
48. Somes GW, Pahor M, Shorr RI, Cushman WC, Applegate WB. The role of
diastolic blood pressure when treating isolated systolic hypertension. Arch
Intern Med. 1999;159:2004–2009.
49. Chirinos JA, Zambrano JP, Chakko S, Veerani A, Schob A, Perez G, Mendez AJ.
Relation between ascending aortic pressures and outcomes in patients with
angiographically demonstrated coronary artery disease. Am J Cardiol.
2005;96:645–648.
50. Selvaraj S, Claggett B, Shah SJ, Anand I, Rouleau JL, Desai AS, Lewis EF, Pitt B,
Sweitzer NK, Pfeffer MA, Solomon SD. Systolic blood pressure and cardio-
vascular outcomes in heart failure with preserved ejection fraction: an analysis
of the TOPCAT trial. Eur J Heart Fail. 2018;20:483–490.
51. Tsujimoto T, Kajio H. Low diastolic blood pressure and adverse outcomes in
heart failure with preserved ejection fraction. Int J Cardiol. 2018;263:69–74.
52. Teng TK, Tay WT, Dahlstrom U, Benson L, Lam CSP, Lund LH. Different
relationships between pulse pressure and mortality in heart failure with
reduced, mid-range and preserved ejection fraction. Int J Cardiol.
2018;254:203–209.
53. Muhammad IF, Borne Y, Ostling G, Kennback C, Gottsater M, Persson M,
Nilsson PM, Engstrom G. Arterial stiffness and incidence of diabetes: a
population-based cohort study. Diabetes Care. 2017;40:1739–1745.
54. Chirinos JA, Phan TS, Syed AA, Hashmath Z, Oldland HG, Koppula MR, Tariq A,
Javaid K, Miller R, Varakantam S, Dunde A, Neetha V, Akers SR. Late systolic
myocardial loading is associated with left atrial dysfunction in hypertension.
Circ Cardiovasc Imaging. 2017;10:e006023.
55. Chirinos JA, Segers P, Gupta AK, Swillens A, Rietzschel ER, De Buyzere ML,
Kirkpatrick JN, Gillebert TC, Wang Y, Keane MG, Townsend R, Ferrari VA,
Wiegers SE, St John Sutton M. Time-varying myocardial stress and systolic
pressure-stress relationship: role in myocardial-arterial coupling in hyperten-
sion. Circulation. 2009;119:2798–2807.
56. Chirinos JA, Segers P, Raina A, Saif H, Swillens A, Gupta AK, Townsend R,
Emmi AG Jr, Kirkpatrick JN, Keane MG, Ferrari VA, Wiegers SE, St John Sutton
MG. Arterial pulsatile hemodynamic load induced by isometric exercise
strongly predicts left ventricular mass in hypertension. Am J Physiol Heart Circ
Physiol. 2010;298:H320–H330.
57. Chirinos JA, Segers P, Gillebert TC, Gupta AK, De Buyzere ML, De Bacquer D,
St John-Sutton M, Rietzschel ER, Asklepios I. Arterial properties as determi-
nants of time-varying myocardial stress in humans. Hypertension.
2012;60:64–70.
58. Al-Badri A, Hashmath Z, Oldland GH, Miller R, Javaid K, Syed AA, Ansari B,
Gaddam S, Witschey WR, Akers SR, Chirinos JA. Poor glycemic control is
associated with increased extracellular volume fraction in diabetes. Diabetes
Care. 2018;41:2019–2025.
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
DOI: 10.1161/JAHA.118.011457 Journal of the American Heart Association 17
Diabetes Mellitus in HFpEF Chirinos et al
D
ow
nloaded from
 http://ahajournals.org by on August 9, 2019
